A physician in O'Fallon, Missouri, has two ways to say the same thing. One: "You may have treatment-resistant depression, and esketamine could be an option." Two: "The medicines you have tried have not done enough, and there is another kind of treatment we could look at." Both are accurate. They land very differently.
This comparison, written for primary care physicians and referrers in O'Fallon and across St. Charles County, sets patient language and clinical language side by side at each stage of a referral conversation. The basis is our survey of 443 Midwest adults, which included a write-in question about the words people would search in a rough patch. Figures are ten-state top-line results, now final after validation.
What patient language sounds like
Of the 443 respondents, 319 wrote an answer to that search question. Their phrases were short and personal, from "ptsd treatments" to "depression medicine alternatives." None named a drug.
That is not surprising given awareness levels. Spravato, which the FDA approved as an esketamine nasal spray for depression that resists treatment, drew a complete blank from 73 percent of respondents, and another fifth could only say they had heard the name. A slim 6 percent had a working idea of what the product is.
Stage one: opening the conversation
Clinical version: "Let's assess whether your depression meets criteria for treatment resistance."
Symptom version: "It sounds like the medicines have not helped enough. Tell me what the last few months have been like."
How each lands. The clinical version can feel like a label, and some patients hear "resistant" as a judgment about them. The symptom version invites the patient to keep talking, which is how you get the history you need. At the opening, patient language usually wins.
Stage two: taking the history
Clinical version: "How many adequate antidepressant trials have you had?"
Symptom version: "Which medicines have you tried? How long did you take each one, and what happened?"
How each lands. Most patients cannot answer the first question as asked. They can answer the second. You then do the translation yourself. This stage calls for patient language in the question and clinical thinking in the listening.
Stage three: introducing the option
Clinical version: "I would like to refer you for esketamine."
Symptom version: "The FDA has approved a nasal spray for depression that ordinary antidepressants have not fixed. You go to a certified clinic for each dose, the staff monitor you until you are ready to leave, and a friend or relative drives you home."
Blended version: The symptom version followed by "It is called Spravato."
How each lands. The bare clinical term means nothing to most patients, given the awareness numbers. The pure symptom version is clear but leaves the patient without a name to look up later. The blended approach is usually best: describe, then name. It also sets up an important distinction. Patients who search the name will find the approved product, and you can hand them a plain Spravato overview to start from. Patients who search "ketamine" may find off-label IV clinics or at-home telehealth services, which are different and less supervised.
Stage four: addressing approval and safety
Clinical version: "It is approved under a REMS program with required post-dose monitoring."
Symptom version: "The FDA has approved it for this kind of depression. Because it can make you feel strange or drowsy for a while, you stay at the clinic afterward until you are cleared, and you do not drive until the next day."
How each lands. Approval matters to patients: 59 percent of respondents called approval deciding or big. The symptom version conveys both the approval and the practical implication. Save the acronym for colleagues.
Stage five: the coverage conversation
Clinical version: "This will require a prior authorization under your medical benefit."
Symptom version: "Your insurance will probably want to approve this first. That takes some paperwork. I will send your medication history so the clinic can make the case."
How each lands. Coverage is where patients pay closest attention. Eighty-five percent of respondents put it in their top two. Here, a small amount of clinical vocabulary is useful. Patients who hear "prior authorization" can use that exact phrase when they call their plan. Offer the term, then explain it.
Stage six: the handout
Clinical version: A manufacturer sheet or a clinic brochure written for prescribers.
Symptom version: A short page that starts with "If your depression has not gotten better on medication," explains the next steps in plain words, and includes the treatment's correct name and the clinic's number.
How each lands. Patients take handouts home and then search. A plain-language sheet with the correct name sends that search in the right direction.
The side-by-side summary
- Opening: patient language.
- History: patient language in the question, clinical thinking in the answer.
- Introducing the option: describe in patient language, then name it.
- Approval and safety: patient language with the key fact stated plainly.
- Coverage: patient language plus one or two terms they will need on the phone.
- Handout: patient language with the correct name included.
Why the choice matters so much
Your words carry more weight than any other source. Seventy-four percent of respondents ranked their own doctor's recommendation above every other voice, and 2 percent said the same of ads. When the most trusted voice speaks in words the patient can hold, the referral has the best chance of becoming a visit. O'Fallon patients will also weigh the drive: 43 percent of respondents listed closeness to home in their top two.
Scope
This comparison reflects survey findings about patient language and choice, not clinical guidance. Candidacy for any treatment is a clinical decision.
If a patient's words turn toward hopelessness or self-harm, the conversation changes. Assess safety and make sure they leave knowing that 988, by call or text, connects to the Suicide and Crisis Lifeline at all hours, and that veterans can press 1.
Methodology
Data comes from a Pollfish panel survey we ran, which closed June 23, 2026. It reached 443 people, 18 to 64, in Kansas, Minnesota, Ohio, Wisconsin, Nebraska, Indiana, Iowa, Illinois, Oklahoma, and Missouri. Search phrases are from 319 open answers. We cite no O'Fallon or county breakout; every figure is ten-state top-line and final. Example dialogue is illustrative. The publisher commissioned and underwrote the survey.